BEIJING, Nov. 17 Sinovac Biotech Ltd. (Nasdaq: SVA),a leading developer and provider of vaccines in China, announced today that itreceived a revised production license from State Food and Drug Administrationfor Panflu.1, the Company's H1N1 vaccine. The population has been expanded toinclude people over 60 years old. The shelf life for PANFLU.1 was extended toone year from six months.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, stated, "Therevised license enables Sinovac to provide our H1N1 vaccine to a broaderpopulation across China and lengthens the product shelf life. We continue towork closely with Chinese government to provide citizens withinternational-quality vaccines and to fulfill our mission of supplyingvaccines to eliminate human diseases."
Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac's vaccineproducts include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A andB), and Anflu(R) (influenza). PANFLU.1(TM), Sinovac's H1N1 vaccine, andPanflu(TM), Sinovac's pandemic influenza vaccine (H5N1), have already beenapproved for government stockpiling. Sinovac is developing vaccines forenterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine,and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is hassubmitted an application for approval with the Ministry of Agriculture for itsindependently developed inactivated animal rabies vaccine.
Safe Harbor Statement
This announcement contains forward-looking statements. These statementsare made under the "safe harbor" provisions of the U.S. Private SecuritiesLitigation Reform Act of 1995. These forward-looking statements can beidentified by words or phrases such as "will," "expects," "anticipates,""future," "intends," "plans," "believes," "estimates" and similar statements.Among other things, the business outlook and quotations from management inthis press release contain forward-looking statements. Statements that are nothistorical facts, including statements about Sinovac's beliefs andexpectations, are forward-looking statements. Forward-looking statementsinvolve inherent risks and uncertainties. A number of important factors couldcause actual results to differ materially from those contained in anyforward-looking statement. Sinovac does not undertake any obligation to updateany forward-looking statement, except as required under applicable law.For further information, please contact: Sinovac Biotech Ltd. Helen G. Yang Tel: +86-10-8289-0088 x9871 Fax: +86-10-6296-6910 Email: [email protected]
Investors: The Ruth Group Amy Glynn/Stephanie Carrington Tel: +1-646-536-7023/7017 Email: [email protected] [email protected]
Media The Ruth Group Janine McCargo Tel: +1-646-536-7033 Email: [email protected]
SOURCE Sinovac Biotech Ltd.